Every material Form 8-K Health In Tech, Inc. has filed with the SEC since September 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Health In Tech, Inc. issued a second promissory note to investor YA II PN, Ltd. on November 2, 2026, with a principal amount of $3.0 million, which provided gross proceeds of $2.85 million after a 5% purchase price discount. The notes are convertible into Class A common stock at a fixed price of $1.5735 per share and can be converted into shares that could dilute existing holders, with an Exchange Cap of 13,100,378 shares that the company is seeking stockholder approval to exceed at its November 10, 2026 annual meeting.
Second promissory note issued November 2, 2026: $3.0 million principal, $2.85 million gross proceeds after 5% discount
Notes mature February 18, 2028, bear 8.75% annual interest (18% after certain defaults), and carry a 4% payment premium unless paid via stock sale proceeds
Conversion price fixed at $1.5735 per share with a floor price of $0.204; Exchange Cap is 13,100,378 shares, about 19.99% of outstanding Class A and Class B common stock
Company seeks stockholder approval to issue shares above the Exchange Cap at its annual meeting on November 10, 2026
Health In Tech appointed Sanjay Shrestha as Chief Executive Officer effective October 20, 2026, succeeding founder Tim Johnson, who became Executive Chairman on the same date. The filing sets out Shrestha's employment terms and restricted stock awards, and part of the equity grant depends on stockholder approval of a plan amendment.
Shrestha, age 52, previously served as a director from April 2025 until his resignation in August 2026.
Base salary is $500,000, increasing to at least $700,000 upon the Company raising at least $10,000,000.
Sign-On Award of 2,000,000 Class A shares; Market Capitalization Awards total 4,500,000 shares.
MC-2, MC-3 and MC-4 tranches (2,500,000 shares) depend on stockholder approval at the November 10, 2026 annual meeting.
Health In Tech received two Nasdaq letters: one because it is not compliant with independent director and audit committee requirements after a director resigned, and one because its Class A shares closed below $1.00 for 30 consecutive business days. Neither letter has an immediate effect on the listing or trading of the stock, but the company faces cure deadlines and could face delisting if it fails to meet them.
Nasdaq letter dated October 14, 2026 cites non-compliance with independent director and audit committee rules after Sanjay Shrestha resigned on August 10, 2026; the Audit Committee has two members, and the company expects a new independent
Cure period for the board and audit committee rules ends at the earlier of the next annual meeting or August 10, 2027; the company must show compliance by February 8, 2027 if that meeting is held before then
Nasdaq letter dated October 12, 2026 cites a closing bid price below $1.00 for 30 consecutive business days; the company has until April 12, 2027 to regain compliance, which could require a reverse stock split
Health In Tech said full-year 2026 revenue is expected to be about $33 million, roughly in line with 2025 revenue, and attributed the outlook mainly to the timing of several strategic initiatives. The company also launched HitRix, an AI-powered platform for large-group self-funded health insurance submissions, and said it expects HitRix and related initiatives to contribute more meaningfully beginning in 2027.
2026 revenue outlook of approximately $33 million, roughly in line with 2025 revenue
Outlook reflects timing of HitRix commercialization, the Three-Year Rate Stabilization Program and additional carrier capacity
HitRix platform launched September 30, 2026, for large-group self-funded health insurance workflows
Distribution ecosystem included 933 partners as of June 30, 2026, up 19.9% year over year
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Health In Tech, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →